Ann: DISCO topline results, page-40

Feature	⁶⁴Cu-SARTATE	⁶⁴Cu-SAR-bisPSMA
Target Molecule	SSTR2 (Somatostatin Receptor 2)	PSMA (Prostate-Specific Membrane Antigen)
Primary Cancer Target	Neuroendocrine tumors (NETs)	Prostate cancer
Other Potential Targets	Some breast and lung cancers with SSTR2	PSMA+ salivary gland or rare tumors (research only)
Diagnostic Agent	⁶⁴Cu-SARTATE (PET)	⁶⁴Cu-SAR-bisPSMA (PET)
Therapeutic Agent	⁶⁷Cu-SARTATE (Therapy)	⁶⁷Cu-SAR-bisPSMA (Therapy)
Molecular Design	Peptide (DOTATATE analogue)	Bispecific PSMA-targeting molecule
Clarity's Technology	SAR Technology + copper pairing	SAR Technology + bispecific PSMA with copper pairing
Imaging Flexibility	Same-day and next-day (⁶⁴Cu half-life ~12.7h)	Same-day and next-day (⁶⁴Cu half-life ~12.7h)
Competing SOC Agent	⁶⁸Ga-DOTATATE	⁶⁸Ga-PSMA-11, ¹⁸F-DCFPyL
Key Competitor Companies	- Novartis/AAA (NETSPOT, ¹⁷⁷Lu-DOTATATE) - ITM (SSTR2 theranostics) - Lantheus (Ga-DOTATATE pipeline)	- Telix Pharmaceuticals (Illuccix) - Novartis/AAA (Pluvicto) - Blue Earth Diagnostics (¹⁸F-DCFPyL/PSMA PET)

The results outcome on CU-SARTATE is amazing !! this will open to more products design. The potential is HUGE
CU-SARTATE is monovalent targeting and the results are outstanding, will replace current SOC
CU-SAR-bisPSMA is bispecific targeting, head to head trail results should be outstanding aswell

There is huge possibility for ⁶⁴Cu-SARTATE to attain FDA Breakthrough Therapy Designation (BTD)